Protocol Ledger

NCT07596849 · Phase III · RECRUITING

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

Interventional Phase III clinical trial protocol NCT07596849 sponsored by argenx in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-10 Enrollment: 230 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07596849
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)230 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07596849
Protocol FieldVerified Registry Value
NCT IdentifierNCT07596849
Consolidated Lead Sponsorargenx
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment230 participants (ESTIMATED)
Registered Start Date2026-06-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07596849
Hospital Research SiteLocationSite Profile
Universitair Ziekenhuis GentGhent, BelgiumOpen Hospital Dossier ->
Okayama University HospitalOkayama, JapanOpen Hospital Dossier ->
Nagasaki University HospitalNagasaki, JapanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI